CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Childrens Oncology Group Genome-Wide Association Study [Pediatric Oncology]

Conclusion
We report a modifying effect of a polymorphism of CELF4 (rs1786814) on the dose-dependent association between anthracyclines and cardiomyopathy, which possibly occurs through a pathway that involves the expression of abnormally spliced TNNT2 variants.

Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Wang, Sun, Quinones-Lombrana, Singh, Landier, Hageman, Mather, Rotter, Taylor, Chen, Armenian, Winick, Ginsberg, Neglia, Oeffinger, Castellino, Dreyer, Hudson, Robison, Blanco, Bhatia Tags: Genetic epidemiology, Long Term Survival & Late Effects Pediatric Oncology Source Type: research